Premium
Antibodies for all: The case for genome‐wide affinity reagents
Author(s) -
Sidhu Sachdev S.
Publication year - 2012
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2012.05.044
Subject(s) - reagent , computational biology , antibody , closing (real estate) , monoclonal antibody , recombinant dna , genome , data science , computer science , chemistry , political science , biology , immunology , biochemistry , gene , law
For more than 30 years, the production of research antibodies has been dominated by hybridoma technologies, while modern recombinant technologies have lagged behind. Here I discuss why this situation must change if we are to generate reliable, comprehensive reagent sets on a genome‐wide scale, and I describe how a cultural shift in the research community could revolutionize and modernize the affinity reagent field. In turn, such a revolution would pay huge dividends by closing the gap between basic research and therapeutic development, thus enabling the development of myriad new therapies for unmet medical needs.